文献速递心力衰竭与心肌病

心力衰竭患者低正常血红蛋白浓度与临床结局的关系

Low-Normal Hemoglobin Concentrations and Clinical Outcomes in Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2026-08-28

该研究汇总了6项HFrEF试验和5项HFpEF/HFmrEF试验的个体数据,共纳入25,003例HFrEF患者和17,210例HFpEF/HFmrEF患者。结果显示,在女性和男性心衰患者中,最低风险对应的血红蛋白浓度分别约为14 g/dL和15 g/dL,均高于WHO贫血阈值。WHO定义的贫血与最高校正风险相关,高于阈值的血红蛋白浓度仍可能具有预后意义。

要点

  • 心衰患者最低风险的血红蛋白浓度约为女性14 g/dL、男性15 g/dL。
  • WHO贫血阈值以上仍存在超额风险,尤其是0至<1 g/dL区间。
  • 高于WHO阈值的血红蛋白水平仍可能提示需关注铁缺乏等可逆因素。

核心结论

  • 在心力衰竭患者中,死亡和心衰住院风险最低的血红蛋白浓度约为女性14 g/dL、男性15 g/dL。
  • 血红蛋白浓度高于WHO贫血阈值时仍可能具有预后信息。

研究设计与样本

  • 患者水平数据来自6项HFrEF试验和5项HFpEF/HFmrEF试验。
  • 共纳入25,003例HFrEF患者,其中女性5,581例、男性19,422例。
  • 共纳入17,210例HFpEF/HFmrEF患者,其中女性8,763例、男性8,447例。
  • 采用Cox比例风险模型分析基线血红蛋白与首次心衰住院或心血管死亡复合终点、各组成事件及全因死亡的关联。
  • 采用带限制性立方样条的Poisson回归估计与最低事件率相关的性别特异性血红蛋白浓度。

主要发现

  • HFrEF中,女性中位血红蛋白为13.0 g/dL(Q1-Q3:12.1-13.9 g/dL),男性为14.0 g/dL(Q1-Q3:12.9-15.1 g/dL)。
  • HFpEF/HFmrEF中,女性中位血红蛋白为13.1 g/dL(Q1-Q3:12.1-14.0 g/dL),男性为14.0 g/dL(Q1-Q3:12.8-15.0 g/dL)。
  • 在所有心衰表型和结局中,最低风险出现在女性约14 g/dL、男性约15 g/dL,均高于WHO贫血阈值。
  • 以血红蛋白≥2 g/dL高于WHO贫血阈值为参照,WHO定义的贫血与最高校正风险相关。
  • 在高于WHO阈值0至<1 g/dL区间也观察到超额风险。

关键数值与推荐

  • WHO贫血阈值定义为女性血红蛋白<12 g/dL、男性<13 g/dL。
  • 最低风险血红蛋白浓度约为女性14 g/dL、男性15 g/dL。
  • 参照组定义为血红蛋白≥2 g/dL高于WHO贫血阈值。

临床怎么用

  • 心衰患者血红蛋白浓度高于WHO贫血阈值时仍应结合其他临床发现评估预后。
  • 高于阈值的血红蛋白水平可能提示需考虑铁缺乏等潜在可逆因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The World Health Organization (WHO) defines anemia as hemoglobin concentration <12 g/dL in women and <13 g/dL in men. Although widely used clinically, these thresholds were based on distributions in healthy populations rather than on outcomes. Whether these WHO thresholds adequately reflect the relationship between hemoglobin concentration and clinical outcomes in patients with heart failure (HF) is uncertain. OBJECTIVES: We sought to characterize sex-specific associations between hemoglobin concentration and clinical outcomes and to identify the hemoglobin concentrations associated with the lowest observed risk in patients with HF across the spectrum of left ventricular ejection fraction. METHODS: Patient-level data were pooled from 6 trials in heart failure with reduced ejection fraction (HFrEF) and 5 trials in heart failure with preserved ejection fraction (HFpEF) or heart failure with mildly reduced ejection fraction (HFmrEF). Associations among baseline hemoglobin and a first HF hospitalization or cardiovascular death, the components of this composite, and all-cause death were examined using Cox proportional hazards models. Sex-specific hemoglobin concentrations associated with the lowest incidence rates were estimated using Poisson regression with restricted cubic splines. Outcomes were also examined by hemoglobin categories defined relative to WHO anemia thresholds. RESULTS: Overall, 25,003 patients with HFrEF (5,581 women, 19,422 men) and 17,210 with HFpEF/HFmrEF (8,763 women, 8,447 men) were included. In HFrEF, median hemoglobin was 13.0 g/dL (Q1-Q3: 12.1-13.9 g/dL) in women and 14.0 g/dL (Q1-Q3: 12.9-15.1 g/dL) in men; corresponding values in HFpEF/HFmrEF were 13.1 g/dL (Q1-Q3: 12.1-14.0 g/dL) and 14.0 g/dL (Q1-Q3: 12.8-15.0 g/dL), respectively. Across HF phenotypes and outcomes, the lowest risk occurred at hemoglobin concentrations of approximately 14 g/dL in women and 15 g/dL in men, above the WHO anemia thresholds. With hemoglobin ≥2 g/dL above the WHO anemia thresholds as the reference, WHO-defined anemia was associated with the highest adjusted risk. Excess risk was also observed at 0 to <1 g/dL above the thresholds. CONCLUSIONS: In patients with HF, hemoglobin concentrations associated with the lowest risk of death and HF hospitalization were approximately 14 g/dL in women and 15 g/dL in men. Hemoglobin concentrations above WHO anemia thresholds may still carry prognostic information and, in conjunction with other clinical findings, may prompt consideration of potentially reversible contributors such as iron deficiency. (Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Added], NCT00634309; Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Alternative], NCT00634400; Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Preserved], NCT00634712; A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF], NCT00232180; Irbesartan in Heart Failure With Preserved Systolic Function [I-Preserve], NCT00095238; Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function [TOPCAT], NCT00094302; This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure [PARADIGM-HF], NCT01035255; Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF], NCT01920711; Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF], NCT03036124; Registrational Study With Omecamtiv Mecarbil [AMG 423] to Treat Chronic Heart Failure With Reduced Ejection Fraction [GALACTIC-HF], NCT02929329; Study to Evaluate the Efficacy [Effect on Disease] and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction [Proportion of Blood Expelled Per Heart Stroke] Greater or Equal to 40% [FINEARTS-HF], NCT04435626).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Chimura, Pellicori, Docherty, et al. Low-Normal Hemoglobin Concentrations and Clinical Outcomes in Heart Failure. J Am Coll Cardiol. 2026. PMID: 42663359. doi:10.1016/j.jacc.2026.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。